Evonik Evonik

X

Find the latest Drugs in Development and Pipeline Prospector News of Helix BioPharma.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Helix BioPharma
Canada Flag
Country
Country
Canada
Address
Address
9120 Leslie Street, Suite 205 Richmond Hill, Ontario L4B 3J9
Telephone
Telephone
905.841.2300
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

MoonLake plans to execute on its development program to unlock the potential of Sonelokimab, the novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients with inflammatory diseases.


Lead Product(s): Sonelokimab

Therapeutic Area: Dermatology Product Name: M1095

Highest Development Status: Phase IIProduct Type: Large molecule

Recipient: MoonLake Immunotherapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination April 05, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Proceeds from the transaction are expected to provide MoonLake with the capital needed to accelerate the development of the clinical stage, tri-specific Nanobody® sonelokimab, in multiple inflammatory diseases in dermatology and rheumatology driven by IL-17A and IL-17F.


Lead Product(s): Sonelokimab

Therapeutic Area: Dermatology Product Name: M1095

Highest Development Status: Phase IIProduct Type: Large molecule

Recipient: MoonLake Immunotherapeutics

Deal Size: Undisclosed Upfront Cash: $230.0 million

Deal Type: Agreement October 04, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

In this next stage, the Company together with Moffit, intends to build on these early successes and provide additional preclinical support in using L-DOS47 with immunotherapies as clinical support.


Lead Product(s): L-DOS47

Therapeutic Area: Oncology Product Name: L-DOS47

Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

Recipient: Moffitt Cancer Center

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration August 12, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Topline data of the recently completed L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer will be published at the ASCO 2020 Annual Conference.


Lead Product(s): L-DOS47,Pemetrexed,Carboplatin

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase IProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY